• Prana Biotechnology Ltd., of Parkville, Australia, said it completed its Phase II Reach2HD trial testing PBT2 in patients with early to midstage Huntington's disease. Results from the 109-patient study are expected in October. The primary outcome is safety and tolerability, with secondary outcomes including measures from the cognitive, motor and behavioral domains affected in Huntington's disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter